Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Pharma Mar S.A. is currently managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct art units, showing a focused but multi-faceted approach to life sciences. The portfolio involves 4 distinct examiners, with each of the 4 pending office actions assigned to a different individual.
CUNNINGCHEN, KATHLEEN MARY is the busiest examiner, though they only hold 1 pending office action. Since each of the 4 distinct examiners manages exactly 1 of the 4 pending office actions, the workload is evenly spread. This distribution across 3 distinct art units requires the company to manage 4 separate prosecution tracks, each with its own examiner-specific nuances. CUNNINGCHEN, KATHLEEN MARY is one of the 4 distinct examiners involved.
The presence of 3 distinct art units indicates that the company's Biotechnology & Pharmaceuticals filings are being evaluated by multiple administrative groups. With 4 distinct examiners providing feedback, the company must be prepared for a variety of prosecution styles. This decentralized structure for the 4 pending office actions ensures that the portfolio's progress is not dependent on the review of any single individual.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUNNINGCHEN, KATHLEEN MARY | 1 | 61.1% | +62.5% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.5% | +49.1% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 59.2% | +42.1% |
| HA, JULIE | 1 | 75.7% | +44.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17908532 | COMPOUNDS FOR USE IN AUTOIMMUNE CONDITIONS | HA, JULIE | 58d overdue |
| 18560991 | DOSAGE REGIMENS FOR ECUBECTEDIN | TOWNSLEY, SARA ELIZABETH | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17908532 | COMPOUNDS FOR USE IN AUTOIMMUNE CONDITIONS | HA, JULIE | 58d overdue |
| 18560991 | DOSAGE REGIMENS FOR ECUBECTEDIN | TOWNSLEY, SARA ELIZABETH | 14d |
| 17920000 | DRUG ANTIBODY CONJUGATES | ROBINSON, MIKHAIL O'DONNEL | 35d |
| 18703491 | LURBINECTEDIN AND ATEZOLIZUMAB COMBINATIONS | CUNNINGCHEN, KATHLEEN MARY | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1627 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18703491 | LURBINECTEDIN AND ATEZOLIZUMAB COMBINATIONS | CUNNINGCHEN, KATHLEEN MARY | — | §102§103§112DP | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18560991 | DOSAGE REGIMENS FOR ECUBECTEDIN | TOWNSLEY, SARA ELIZABETH | 1629 | §112 | Non-Final OA | 14d | Pending | Nov 15, 2023 |
| 17920000 | DRUG ANTIBODY CONJUGATES | ROBINSON, MIKHAIL O'DONNEL | 1627 | §112 | Final Rejection | 35d | Pending | Oct 19, 2022 |
| 17908532 | COMPOUNDS FOR USE IN AUTOIMMUNE CONDITIONS | HA, JULIE | 1654 | §102§103§112 | Final Rejection | 58d overdue | Pending | Aug 31, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial